Rondon A, Featherby S, Gomes T, Laghmani E, Ettelaie C, Versteeg H
J Thromb Thrombolysis. 2025; .
PMID: 40042717
DOI: 10.1007/s11239-025-03076-4.
Tamminen A, Aaltonen R, Ristola M
World J Surg Oncol. 2025; 23(1):68.
PMID: 40022174
PMC: 11869587.
DOI: 10.1186/s12957-025-03712-6.
Shapoo N, Boma N, Chaudhari S, Gotlieb V
Hematol Rep. 2025; 17(1).
PMID: 39997356
PMC: 11854944.
DOI: 10.3390/hematolrep17010008.
Abbas U, MacKenzie R, Khan U, Fatima R, Wang T, Luo R
Res Pract Thromb Haemost. 2025; 9(1):102684.
PMID: 39990096
PMC: 11847241.
DOI: 10.1016/j.rpth.2025.102684.
Cornish N, Westbury S, Warkentin M, Thirlwell C, Mumford A, Haycock P
Wellcome Open Res. 2025; 9:640.
PMID: 39931111
PMC: 11809147.
DOI: 10.12688/wellcomeopenres.23156.1.
Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer Associated Thrombosis: Experience From a Resource Limited Setting.
Tasamma A, Bukate T, Mehadi A, Handiso B, Kassa B, Hassen E
Cancer Rep (Hoboken). 2025; 8(1):e70105.
PMID: 39846434
PMC: 11755349.
DOI: 10.1002/cnr2.70105.
External validation of a novel cancer-associated venous thromboembolism risk assessment score in a safety-net hospital.
Dulberger K, La J, Li A, Lotfollahzadeh S, Jose A, Do N
Res Pract Thromb Haemost. 2025; 9(1):102650.
PMID: 39839661
PMC: 11745955.
DOI: 10.1016/j.rpth.2024.102650.
Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising-VTE/NEJ037 Study.
Furuya N, Tsubata Y, Hotta T, Yokoyama T, Yamasaki M, Ishikawa N
Cancer Med. 2025; 14(1):e70568.
PMID: 39783855
PMC: 11714229.
DOI: 10.1002/cam4.70568.
Extent of peritoneal metastases from colorectal cancer is not associated with changes in thrombin generation or fibrinolysis.
Lundbech M, Krag A, Iversen L, Brandsborg B, Hvas A
Pleura Peritoneum. 2024; 9(4):149-154.
PMID: 39712293
PMC: 11661465.
DOI: 10.1515/pp-2024-0009.
High Rate of Thromboembolic Events in the Last Year of Life of Cancer Patients: A Registry Study.
Strang P, Schultz T
Cancers (Basel). 2024; 16(23).
PMID: 39682217
PMC: 11640034.
DOI: 10.3390/cancers16234031.
Venous thromboembolism and mortality in patients with hematological malignancies.
Sanfilippo K, Wang T
Bleeding Thromb Vasc Biol. 2024; 3(Suppl 1).
PMID: 39669477
PMC: 11636961.
DOI: 10.4081/btvb.2024.119.
Incidence and risk factors of ischemic stroke in patients with cancer-associated venous thromboembolism: from the Contemporary Management and Outcomes in Patients With Venous Thromboembolism Registry-2.
Sato T, Ogihara Y, Yamashita Y, Morimoto T, Chatani R, Kaneda K
Res Pract Thromb Haemost. 2024; 8(8):102617.
PMID: 39634322
PMC: 11616038.
DOI: 10.1016/j.rpth.2024.102617.
Thromboembolism in Patients with Cancer: A Practical Guide to Recurrent Events.
Kozhukhov S, Dovganych N
Rev Cardiovasc Med. 2024; 25(11):406.
PMID: 39618864
PMC: 11607493.
DOI: 10.31083/j.rcm2511406.
The Basic Principles of Pathophysiology of Venous Thrombosis.
Schulman S, Makatsariya A, Khizroeva J, Bitsadze V, Kapanadze D
Int J Mol Sci. 2024; 25(21).
PMID: 39519000
PMC: 11547114.
DOI: 10.3390/ijms252111447.
Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study.
Beckmann M, Schluter J, Erdmann M, Kramer R, Cunningham S, Hackstein H
Cancer Immunol Immunother. 2024; 74(1):5.
PMID: 39487855
PMC: 11531462.
DOI: 10.1007/s00262-024-03850-y.
The factors affecting the survivability of malignant cancer patients with deep vein thrombosis among subjects with gynecologic and non-gynecologic cancer: An ambispective cohort study.
Rachman A, Christine G, Betsy R, Juanputra S, Pratiwi W
F1000Res. 2024; 12:890.
PMID: 39479230
PMC: 11522705.
DOI: 10.12688/f1000research.135252.2.
Pharmacodynamics of Rivaroxaban and Dabigatran in Adults with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy.
Punnachet T, Cressey T, Apiwatnakorn P, Koonarat A, Norasetthada L, Tantiworawit A
Pharmaceutics. 2024; 16(10).
PMID: 39458648
PMC: 11511075.
DOI: 10.3390/pharmaceutics16101319.
Comprehensive Analysis of a Platelet- and Coagulation-Related Prognostic Gene Signature Identifies CYP19A1 as a Key Tumorigenic Driver of Colorectal Cancer.
Su G, Wang M, Qian J, Wang Y, Zhu Y, Wang N
Biomedicines. 2024; 12(10).
PMID: 39457539
PMC: 11505370.
DOI: 10.3390/biomedicines12102225.
Survival and cardiovascular disease mortality among primary liver cancer patients: A population-based study.
Wang L, Wang T, Zhang W, Zheng S
Heliyon. 2024; 10(19):e37869.
PMID: 39386844
PMC: 11462467.
DOI: 10.1016/j.heliyon.2024.e37869.
Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis.
Qi Y, Wang X, Guo T, You T, Wang P
BMJ Open. 2024; 14(9):e078173.
PMID: 39349372
PMC: 11448140.
DOI: 10.1136/bmjopen-2023-078173.
